BL
ALNY icon

Balentine LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Balentine LLC’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16
Closed -$2K – 173
2020
Q2 		$2K Sell
16
-112
-88% -$15.1K ﹤0.01% 825
2020
Q1 		$14K Buy
+128
New +$14.8K ﹤0.01% 314

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Balentine LLC's ALNY Position: Q3 2020 in Review

Balentine LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2020, closing a stake of 16 shares — an estimated $2K sold.

Balentine LLC first reported a position in ALNY in Q1 2020 and held it in 2 quarters. The position peaked at $14K in Q1 2020. 356 funds tracked by Wall St. Rank hold ALNY as of Q3 2020.

  • Balentine LLC reported no remaining Alnylam Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Balentine LLC sold 16 Alnylam Pharmaceuticals shares in Q3 2020, an estimated $2K.
  • Balentine LLC first reported a position in Alnylam Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Balentine LLC's Alnylam Pharmaceuticals position peaked at $14K in Q1 2020.
  • 356 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2020.

Based on Balentine LLC's 13F filing for Q3 2020, filed 2 Nov 2020.